Excellent review article by @ptarantinomd.bsky.social on redefining Her-2 testing @ethicsdoctorp.bsky.social @acochran12733.bsky.social ascopubs.org/doi/10.1200/... @oncoalert.bsky.social
13.05.2025 22:06 — 👍 2 🔁 2 💬 0 📌 0
✨EXCLUSIVE PREVIEW: Ahead of the 2025 @ascocancer.bsky.social Annual Meeting, breast cancer experts highlight this year's most anticipated abstracts @stolaney1.bsky.social @ptarantinomd.bsky.social #ASCO25 #bcsm www.onclive.com/view/breast-...
14.05.2025 12:16 — 👍 3 🔁 1 💬 0 📌 0
#ESMOBreast25: Do not miss the latest research findings in #BreastCancer brought to you by the #ESMOAmbassadors & become part of the conversation. #bcsm
🔗 ow.ly/VtAE50VP4Jf
12.05.2025 07:32 — 👍 6 🔁 4 💬 1 📌 0
Congratulations to Drs. Paolo Tarantino, Caterina Sposetti, Pietro De Placido, and Tess O'Meara on receiving the prestigious #ConquerCancer #ASCO Merit Awards!
@ptarantinomd.bsky.social @csposettimd.bsky.social
25.04.2025 12:43 — 👍 5 🔁 2 💬 0 📌 0
Don't miss "The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development," a Cancer Discovery review by #AACR25 speakers Elisabeth de Vries and @raffcolo.bsky.social (along with Pat LoRusso & @ptarantinomd.bsky.social) doi.org/10.1158/2159...
26.04.2025 16:00 — 👍 15 🔁 4 💬 3 📌 0
2025 is anticipated to be the year with the highest number of phase 3 ADC trials read outs in breast oncology, with impact for all breast cancer subtypes.
Here’s 8 ADC breast cancer trials expected to reshape practice in 2025:
15.02.2025 17:07 — 👍 7 🔁 3 💬 0 📌 1
Check out this new systematic review and meta-analysis discussing #AntibodyDrugConjugates in patients with advanced/metastatic HER2-low-expressing #BreastCancer.
🔓https://pubmed.ncbi.nlm.nih.gov/39574495/
@ptarantinomd.bsky.social
17.12.2024 14:30 — 👍 10 🔁 3 💬 1 📌 0
No standing ovations at #SABCS24, but maybe there should have been! 🎤 (Granted, I didn’t catch everything in the room.)
For MBC, the #PATINA and #EMBER data bring meaningful progress for patients with ER+ & triple-positive breast cancer. Exciting strides being made.
13.12.2024 21:36 — 👍 28 🔁 8 💬 2 📌 0
‼️When you thought you had the #SABCS24 program figured out, here’s the PRACTICE-CHANGING #PATINA trial being added!
For the impatient ones, press release here: www.businesswire.com/news/home/20...
If you’re in San Anyonio, though, make sure to attend the data presentation today by Otto Metzger!
12.12.2024 14:55 — 👍 16 🔁 2 💬 0 📌 0
Dr. Paolo Tarantino (@ptarantinomd.bsky.social) will serve as a moderator in the #SABCS24 Educational Session 7. He will also give a presentation titled “Aiming for the Target: Increasing the Precision of #ADCs through Novel Biomarkers and Innovative Molecular Constructs”
11.12.2024 00:24 — 👍 7 🔁 2 💬 0 📌 0
Dr. Paolo Tarantino (@ptarantinomd.bsky.social) will be the invited discussant for Session 8: “Novel HER2 Therapeutics” at #SABCS24, his discussion will focus on #RadiationOncology.
🗓️ Thursday, December 12th
⏰ 7:30 - 7:45 am CST (8:30 – 8:45 am EST)
📍 Stars at Night 1-2
11.12.2024 17:58 — 👍 4 🔁 1 💬 0 📌 0
Outstanding spotlight poster discussion by Thomas Grinda from Gustave Roussy. Promising results with the 1L combination of chemo, IO and VEGF blockade for mTNBC. Will the inclusion of IO in the combo change the story of VEGF, previously thought not to improve long-term outcomes for breast cancer?
11.12.2024 14:13 — 👍 13 🔁 4 💬 0 📌 1
#SABCS24 day 1 kicks off with an interesting @FDAOncology special session on drug approval. First talk tackles the approval of adjuvant ribociclib per NATALEE. Two post-marketing commitments: to provide efficacy in a broader diverse population, and to provide updates on OS. #bcsm
10.12.2024 18:20 — 👍 5 🔁 1 💬 0 📌 0
Awesome #SABCS24 starter pack! 👇
10.12.2024 06:38 — 👍 6 🔁 3 💬 0 📌 0
Small preview from Wednesday’s #SABCS24 session on the future of ADCs
Question: what do all these ongoing phase 3 ADC trials have in common?
🗓️ Dec 11, 3.30 pm, Hemisfair Ballroom 1-2
09.12.2024 21:45 — 👍 12 🔁 2 💬 0 📌 0
#SABCS24 here we go!!
09.12.2024 14:51 — 👍 3 🔁 0 💬 0 📌 0
The @dfcibreastonc.bsky.social team is on its way— see you all soon in San Antonio! #SABCS24
09.12.2024 14:49 — 👍 21 🔁 3 💬 1 📌 0
The European Society for Medical Oncology (ESMO) is a reference organisation for cancer education and information, supporting the oncology community’s work.
Advancing education, research, and innovation in hematology & oncology. #CancerPrevention #CancerAwareness #CancerSurvivors #CancerCare #HealthEquity #GlobalOncology #GlobalHealth #LGBTQ+🏳️🌈💙
Follow Us: https://buff.ly/MWm1IOU
Publishing the latest advances across all areas of cancer research and oncology. Part of @natureportfolio.nature.com
🌐 www.nature.com/natcancer/
📍New York, London, Berlin and Heidelberg
Medical Oncologist specializing in breast cancer research and treatment. Opinions are my own. Not medical advice.
🎥 Start here: trusted cancer info
New videos weekly—subscribe below ⬇️
https://youtu.be/vcetk3Ixiv0?si=70_ooCr-9ytO2G6y
Breast Medical Oncologist @mdanderson.bsky.social #bcsm #oncsky
Hematologist/Oncologist; Co-Founder, President & CEO, Binaytara | Advocate for Equitable Healthcare Access | Innovator in Oncology Education and Global Health
https://binaytara.org
Medical Oncologist /Cardio-Oncologist
Wilmot Cancer Institute
Professor of Medicine, University of Rochester
Director of the Judy DiMarzo Survivorship program
Director of Cardio-Oncology
Rochester, New York
President International Cardio-Oncology Society
Professor Medical Oncologist; Breast cancer specialist; Group leader. Peter MacCallum Cancer Centre, Melbourne Australia;
ETOP-IBCSG
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.
Patient-centered care, clinical trials & translational research on breast cancer @danafarber.bsky.social and Harvard Medical School.
Appts: 877-442-3324, Clinical trials: 877-338-7425
Assistant Professor Breast Medical Oncology, The Ohio State University
👨⚕️Medical Oncologist at Rome.
⚕️Palliative Care researcher, Health Policy ambassador.
🏃♂️Husband, Dad, runner and sport reading addicted.
🏀 NBA lover.
Thoracic Oncologist, Royal Marsden Hospital | Professor, Institute of Cancer Research | Past chair, British Thoracic Oncology Group | Views are my own
Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Kohberg Professor of Medicine, Harvard Medical School
Advancing oncology care through research, innovation, and multidisciplinary collaboration. Passionate about patient-centered solutions, PROs, HRQOL, and evidence-based practices, w a focus on #GUOnc, #GeriOnc & #PallOnc
#ASCO25 FCOI: http://bit.ly/344gKxq
